Author

F. Bost

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

V. Tiroille· 3 shared M. Irondelle· 2 shared A. Baeri· 1 shared A. gutierrez-Guerrero· 1 shared A. Krug· 1 shared A. Lamit· 1 shared A. Mazzu· 1 shared A.-S. GAY· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

V. Tiroille

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma

J. Contenti, Y. Guo, M. Larcher, L. Mirabal-Ortega, M. ROULEAU, M. Irondelle, V. Tiroille, A. Mazzu, V. Duranton-Tanneur, F. Pedeutour, I. Ben-Sahra, C. Lago, G. Leva, L. Tiberi, G. Robert, , N. M. Mazure

This study shows that Group 3 medulloblastoma cells rely on HIF-2 instead of HIF-1 for hypoxia adaptation, and inhibiting HIF-2 with metformin kills these cells more effectively than non-Group 3 cells.

bioRxiv · Oct 17, 2023Cancer Biology

Nanoblades allow high-level genome editing in organoids

V. Tiroille, A. Krug, E. Bokobza, M. Bulcaen, M. Ensinck, M. Geurts, D. Hendriks, F. Vermeulen, F. Larbret, A. gutierrez-Guerrero, M. Louise, R. Gijsbers, P. E. Mangeot, H. Clevers, M. Carlon, , E. Verhoeyen

This paper introduces nanoblade technology for efficient, low-toxicity genome editing in organoids, achieving up to 80% gene knockout in murine and human organoids.

bioRxiv · Aug 4, 2022 · PreprintBioengineering

Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics

B. Cambien, K. Lebrigand, A. Baeri, N. Nottet, C. Compin, A. Lamit, O. Ferraris, C. Peyrefitte, V. Magnone, J. Henriques, L.-E. Zaragosi, S. Giorgetti-Peraldi, F. Bost, M. Gautier-Isola, R. Rezzonico, , G. Vassaux

This paper uses single-cell transcriptomics to identify DDIT4 as a resistance factor against oncolytic vaccinia virus in canine TNBC cells.

bioRxiv · May 29, 2020Cancer Biology

UBTD1 regulates ceramide balance and endolysosomal positioning to coordinate EGFRsignaling

S. TORRINO, V. TIROILLE, B. DOLFI, M. DUFIES, C. HINAULT, L. BONESSO, S. DAGNINO, J. P. UHLER, M. IRONDELLE, A.-S. GAY, L. FLEURIOT, D. Debayle, S. LACAS-GERVAIS, M. CORMONT, T. BERTERO, , S. CLAVEL

This study shows UBTD1 regulates EGFR signaling by controlling ceramide levels and endolysosomal positioning through ubiquitination of ASAH1 and SQSTM1/p62.

bioRxiv · May 20, 2020Cell Biology